Stocks · News reference
IDEAYA Sets November R&D Day To Share New Pancreatic Cancer Research And Strategy
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
IDEAYA Reaches FDA Agreement On Late-Stage Trial Plan For Lung Cancer Drug, Plans Phase 3 Lung Cancer Study For IDE849 By Year-End 2026
IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
Collaboration to to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class MTA-cooperative PRMT5 inhibitor, in combination with GDC-7035 (RG6620), Genentech's KRAS G12D inhibitor,